Browse the evidence

Meta-regression suggested no significant correlation between BP reduction and baseline characteristics such as age, gender, HbA1c, weight, BMI, and percentage of patients with hypertension.

GLP-1 receptor agonists may be effective for BP management regardless of certain baseline characteristics.

Obesity is a disorder of energy metabolism characterized by low usable energy (ATP) in the setting of elevated total energy.

Practitioners should consider the role of energy metabolism in obesity management.

Treatment response heterogeneity is an important area of research in personalized and precision medicine.

Researchers should focus on understanding individual responses to treatments in nutrition and obesity.

New pharmacological treatments for obstructive sleep apnea (OSA) might be effective.

Practitioners should consider new pharmacological options for treating OSA.

Sustained remission was observed in 15.8 % (n = 19) over three years and in 12.5 % (n = 15) over four years.

Sustained remission can be a realistic goal for patients on a very low carbohydrate diet.

Tirzepatide, a GLP-1/GIP receptor co-agonist, was approved by the FDA for the treatment of T2DM and provides superior HbA1c reductions.

Healthcare providers can utilize tirzepatide as a more effective treatment option for T2DM.

The safety profile of tirzepatide is consistent across all phase 3 trials.

Practitioners can expect a consistent safety profile when prescribing tirzepatide.

Effect sizes of GLP-1 receptor agonists in schizophrenia are mostly smaller than in the general population.

While GLP-1 receptor agonists can aid in weight loss, practitioners should manage expectations regarding the magnitude of effect in this population.

Future trials of GLP-1 receptor agonists could focus on dual or triple agonist agents.

Exploring dual or triple agonist therapies may enhance treatment options for weight management in schizophrenia.

A semisupervised high-intensity interval training (HIT) intervention did not increase menstrual frequency in women with PCOS after 12 months.

Practitioners should note that HIT may not improve menstrual frequency in women with PCOS.

MYOD1, MYF5, and MYF6 mean methylation was reduced after 4 and 8 hours in response to all exercise protocols.

Resistance, high-intensity interval, and concurrent exercise can effectively reduce DNA methylation in myogenic regulatory factors.

Changes in DNA methylation and mRNA expression were largely confined to the late (4-8 h) recovery period.

Recovery periods after exercise are critical for observing changes in muscle regulatory factors.

Lesser known factors such as cerebral blood flow, food cue reactivity, gut hormone levels, and dietary adherence possibly impact variability of response to liraglutide.

Healthcare providers should consider these lesser-known factors when evaluating patient responses to liraglutide.

Ten proteins were associated with different rates of weight regain, some specifying pathways of chemotaxis and innate immune responses.

Identifying specific proteins may help tailor interventions for weight regain.

24% of patients with diabetes and delayed gastric emptying were on a GLP-1 receptor agonist.

Practitioners should be aware that a notable percentage of diabetic patients with delayed gastric emptying are using GLP-1R agonists.

GLP-1 receptor agonists use was associated with delayed gastric emptying in patients with diabetes for less than 10 years.

Clinicians should consider the duration of diabetes when prescribing GLP-1R agonists.

The study could not establish statistical significance regarding the likelihood of delayed gastric emptying in patients on GLP-1R agonists.

Further research is needed to clarify the relationship between GLP-1R agonists and gastric emptying.

Semaglutide has a higher pooled reporting odds ratio (ROR) for gastrointestinal adverse drug reactions (GADRs) compared to liraglutide (5.53 vs 3.95).

Clinicians should consider the higher gastrointestinal risk associated with semaglutide when prescribing.

Semaglutide has a later pooled time-to-onset median of GADRs compared to liraglutide (7 days vs 4 days).

Healthcare providers should be aware of the delayed onset of gastrointestinal issues with semaglutide.

Naltrexone/bupropion increased proglucagon levels and decreased GLP-2, glucagon, and the major proglucagon fragment.

Naltrexone/bupropion may be beneficial for altering specific hormone levels related to metabolism.

Lifestyle interventions and older antiobesity pharmacotherapies have been associated with less than 12% body weight reduction and no clear benefit to reduce MACE risk.

Practitioners should be aware that traditional weight loss methods may not significantly reduce cardiovascular risks.

Retatrutide increased heart rate by up to 6.7 beats/min, which may offset some benefits of weight loss.

Weight loss treatments like retatrutide may have cardiovascular implications that need to be considered.

Common cardiovascular conditions, such as heart failure with preserved ejection fraction, can be conceptualized as a consequence of accelerated aging.

Understanding the link between aging and heart failure can guide prevention and management strategies.

Genetic predisposition to higher waist-to-hip ratio adjusted for BMI (WHRadjBMI) predicts an increase in waist circumference after weight loss.

Practitioners should consider genetic predisposition when assessing potential waist circumference changes after weight loss.